TY - JOUR
T1 - Treatment of chronic graft-versus-host disease with bortezomib
AU - Pai, Chien Chun Steven
AU - Chen, Mingyi
AU - Mirsoian, Annie
AU - Grossenbacher, Steven K.
AU - Tellez, Joseph
AU - Ames, Erik
AU - Sun, Kai
AU - Jagdeo, Jared
AU - Blazar, Bruce R.
AU - Murphy, William J.
AU - Abedi, Mehrdad
N1 - Publisher Copyright:
© 2014 by The American Society of Hematology.
PY - 2014
Y1 - 2014
N2 - Chronic graft-versus-host disease (cGVHD) following allogeneic hematopoietic stem cell transplantation (HSCT) has emerged as a predominant complication following HSCT and has a distinct etiology. We and others have previously demonstrated that bortezomib, a proteasome inhibitor, can prevent but not treat acute GVHD in mice. To assess the effects of bortezomib on cGVHD, a mouse minor histocompatibility antigen-mismatched strain combination was used to mimic clinical cGVHD sclerodermatous pathogenesis and phenotype. Treatment of ongoing cGVHD with bortezomib ameliorated cutaneous lesions, which were also associated with a reduction in total numbers of germinal center Bcells and lower B-cell activating factor gene expression levels in cutaneous tissues. Importantly, lymphoma-bearing mice receiving allogeneic HSCT with bortezomib preserved graft-versus-tumor (GVT) effects.Based on these animal studies, we initiated an intrapatient dose escalation clinical trial in patients with extensive steroid-intolerant, dependent, or resistant cGVHD. Marked clinical improvement was observed in patients, which was also associated with reductions of peripheral B cells and minimal toxicity. These results indicate that bortezomib can be of significant use in the treatment of cGVHD and may also allow for maintenance of GVT. This trial was registered at www.clinicaltrials.gov as #NCT01672229.
AB - Chronic graft-versus-host disease (cGVHD) following allogeneic hematopoietic stem cell transplantation (HSCT) has emerged as a predominant complication following HSCT and has a distinct etiology. We and others have previously demonstrated that bortezomib, a proteasome inhibitor, can prevent but not treat acute GVHD in mice. To assess the effects of bortezomib on cGVHD, a mouse minor histocompatibility antigen-mismatched strain combination was used to mimic clinical cGVHD sclerodermatous pathogenesis and phenotype. Treatment of ongoing cGVHD with bortezomib ameliorated cutaneous lesions, which were also associated with a reduction in total numbers of germinal center Bcells and lower B-cell activating factor gene expression levels in cutaneous tissues. Importantly, lymphoma-bearing mice receiving allogeneic HSCT with bortezomib preserved graft-versus-tumor (GVT) effects.Based on these animal studies, we initiated an intrapatient dose escalation clinical trial in patients with extensive steroid-intolerant, dependent, or resistant cGVHD. Marked clinical improvement was observed in patients, which was also associated with reductions of peripheral B cells and minimal toxicity. These results indicate that bortezomib can be of significant use in the treatment of cGVHD and may also allow for maintenance of GVT. This trial was registered at www.clinicaltrials.gov as #NCT01672229.
UR - http://www.scopus.com/inward/record.url?scp=84907013113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907013113&partnerID=8YFLogxK
U2 - 10.1182/blood-2014-02-554279
DO - 10.1182/blood-2014-02-554279
M3 - Article
C2 - 25009225
AN - SCOPUS:84907013113
SN - 0006-4971
VL - 124
SP - 1677
EP - 1688
JO - Blood
JF - Blood
IS - 10
ER -